Co-Authors
This is a "connection" page, showing publications co-authored by GIRISH SHROFF and AJAY SHESHADRI.
Connection Strength
1.827
-
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis. Clin Lung Cancer. 2024 Nov; 25(7):624-633.e2.
Score: 0.245
-
Drug-induced Lung Disease in the Oncology Patient: From Cytotoxic Agents to Immunotherapy. Clin Chest Med. 2024 Jun; 45(2):325-337.
Score: 0.239
-
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist. 2023 Nov 02; 28(11):e1065-e1074.
Score: 0.232
-
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol. 2023; 14:1249511.
Score: 0.231
-
Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer: A prospective cohort study. Cancer Med. 2023 09; 12(17):17753-17765.
Score: 0.229
-
Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clin Oncol (R Coll Radiol). 2023 10; 35(10):630-639.
Score: 0.227
-
Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer. Radiographics. 2022 Nov-Dec; 42(7):1956-1974.
Score: 0.216
-
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer. 2022 07 15; 128(14):2736-2745.
Score: 0.209